The benefits of anti-hypertensive drug treatment have been established by clinical trials demonstrating significant reductions in cardiovascular morbidity and mortality. Thiazide diuretics predominated in these trials but it is reaasonable to conclude that the benefits were attributable to the blood pressure (BP) reduction per se and not to specific pharmacological characteristics. Furthermore, it can be calculated that even greater benefits would probably have accrued if the magnitude of the BP reduction had been greater. On first principles, therefore, the basic requirement for any anti-hypertensive drug is confirmation of its ability to reduce BP. The angiotensin II antagonists constitute an important new class of drug, with a low incidence of adverse effects, but early studies with the prototype, losartan, have
Introduction
There is no doubt that the angiotensin II receptor (AT 1 ) antagonists constitute an exciting and important new class of anti-hypertensive drug. However, for any new agent, or any new class of drug, there remains a requirement to satisfy some basic criteria to demonstrate that theoretical and potential advantages translate to tangible clinical advantages. Some of the basic issues, with the emphasis on fundamental and pragmatic requirements, are listed in Table 1 . Thus, at this early stage in the development of any new drug class, the focus is upon clinical usefulness while awaiting further clarifying information about the overall therapeutic profile. Ultimately, of course, it will be necessary to demonstrate beneficial effects on cardiovascular morbidity and mortality. In one respect there is little doubt that the angiotensin II receptor antagonists, as a class, constitute a clear advance by virtue of their very low rates for adverse events, both symptomatic and metabolic, and particularly the lack of any obvious class-specific adverse effect. Furthermore, in line with current preferences in the treatment of hypertension these drugs are licensed for use as once-daily agents to promote patient convenience and compliance. There is, of course, one remaining fundamental requirement for any new anti-hypertensive drug or drug class: namely, the clear demonstration of an anti-hypertensive efficacy which is at least comparable to that of established agents and which, ideally, might prove superior to that of established agents. It is additionally desirable if the anti-hypertensive effect is readily additive to that of other agents since a significant number of hypertensive patients require combination drug treatment, particularly when optimal blood pressure (BP) values are targeted. Finally, it is important to have clear information about the clinically useful dose range, the dose-response relationships and the dose titration steps which are relevant for routine practice. With particular respect to these issues of the 'quality' of the BP reduction, and the clinically relevant dose range, there is a relative paucity in the published literature of good quality clinical studies which clarify these issues for the angiotensin II antagonist class. Even for the prototype drug in this class, losartan, there is a relative lack of this type of clarifying information and those studies which have addressed such issues have seldom produced definitive answers.
Pharmacokinetic background
With most anti-hypertensive agents it is possible to explore the duration of action and the pharmacokinetic-pharmacodynamic relationships (concentration effect relationships) through careful study of the drug concentration-time profiles. However, it is readily apparent that a simplistic appraisal of the concentration-time profiles with losartan, for example, is not helpful. Losartan itself, and the major pharmacologically active metabolite, EXP3174, both show wide fluctuations between their peak and trough plasma drug concentrations. EXP3174, however, which contributes the greater part of the pharmacological effect of administered losartan, is dependent for its action upon non-competitive binding to the AT 1 receptor. Thus, it is impossible to make a simplistic and direct extrapolation from the concentration-time profile for measured drug concentrations to derive an index of the response-time profile for the measured anti-hypertensive effect. Unfortunately, there are not yet published studies which investigate in close detail the pharmacokinetic-pharmacodynamic relationship for losartan (and EXP3174). Correspondingly, there are no studies with any other angiotensin II antagonists (many of which display a similar type of non-competitive receptor binding) to define their pharmacokinetic-pharmacodynamic relationships. Conventional pharmacokinetic parameters, therefore, do not readily permit direct comparisons of one angiotensin II antagonist with another angiotensin II antagonist. Thus, the drug concentration-time profiles cannot directly be used as surrogate markers for the anti-hypertensive effect-time profiles.
Pharmacodynamic studies

Magnitude and duration of anti-hypertensive effect
At an early stage in clinical development it is possible to explore the duration of action, the doseresponse relationships and the comparability of drugs which have similar mechanisms of action (ie, ACE inhibitor drugs or other angiotensin II antagonists) through clinical pharmacological studies such as those using the salt deplete human normotensive model. This constitutes a convenient and reproducible model albeit best suited to single dose studies. In this respect some possible concerns about the duration of action of losartan were identified in early studies and these are illustrated in a comparative study of single doses of losartan and lisinopril. 1 In this model there was little difference in the maximum or peak BP reductions in normotensive (salt deplete) volunteers, but there appeared to be a separation of the responses at approximately 24 h post-dose whereby a persisting BP reduction was seen with the ACE inhibitor, but the measured BPs were closely similar for both placebo and losartan at this time.
The clinical development programme obviously involves steady-state treatment in hypertensive patients and a number of clinical efficacy studies have now been published. The results of such studies with losartan, for example, show an overall comparability whereby the anti-hypertensive response to losartan is similar to, and not statistically different from, those of reference agents from different drug classes. However, although the overall message is that losartan displays comparable anti-hypertensive activity to most other agents there is also a relative consistency in these early comparative studies whereby the value for losartan always appeared to be less than that of the comparative agent. This paper focuses attention on enalapril as as an illustrative reference comparitor anti-hypertensive drug with a related mechanism of action.
In a double-blind, direct comparison of losartan and enalapril in 407 hypertensive patients, a small and statistically significant difference was identified in favour of the ACE inhibitor in the magnitude of the BP reductions for both systolic and diastolic BP ( Figure 1) . 2 Although the magnitude of this difference was small (2-3 mm Hg) it was identified at 24 h post-dose when the effect of once-daily enalapril itself is known to be only modest. A remarkably similar result was seen in a comparison of 100 mg losartan and 20 mg enalapril which also assessed trough:peak ratio. 3 The trough:peak ratio for losartan was calculated to be satisfactory at 72% but this was achieved with a trough BP reduction of only 4.2 mm Hg (see Table 2 ). Thus, although a high trough:-peak ratio is an index of duration of action and suitability for the recommended dose interval, this comparative study with enalapril again raises questions about the overall magnitude of the anti-hypertensive efficacy of losartan at both trough and peak.
Dose-response relationships
There is also a lack of definitive, published information about the dose-response relationship for losartan. This has been explored in some of the comparative clinical trials but there are again difficulties in clearly identifying statistically significant differences (and clinically relevant differences) between 50 mg, 100 mg and 150 mg losartan. For example, again using enalapril as the reference agent there was no differentiation between the three different losartan doses for either the peak or trough BP reductions (Table 3) . 4 Additionally, there were again superior BP reductions at both peak and trough with enalapril (albeit not of statistical significance).
Comparisons of angiotensin II antagonist drugs
The salt deplete human volunteer model has been used to compare single doses of losartan and candesartan and there is evidence to suggest that both the magnitude of the BP reduction and also the duration, of the anti-hypertensive effect were both inferior with losartan (50 mg) relative to two doses of candesartan cilexetil (8 and 16 mg). 5 Single dose Some corroborative support concerning the duration of action of candesartan is also seen in a separate short term study showing clear evidence of the 24-h duration of action of candesartan cilexetil (32 mg) and the consistency of its anti-hypertensive effect throughout 24 h. 7 Thus, the available published information suggests that candesartan may have an anti-hypertensive effect of greater magnitude and of longer duration than losartan. However, it must be noted that there also remain some doubts as to whether or not the dose range and doseresponse relationship for candesartan have been fully and definitively explored since these various studies have employed dosages from 8 to 32 mg.
With respect to angiotensin II antagonists other than losartan the available but limited information from comparative studies (whilst recognising their limited discriminatory powers) appears to provide a consistent trend for equivalence with comparator anti-hypertensive drugs without the suspicion of an underlying trend of poorer performance. For example, in a comparison between telmisartan and atenolol there was an overall similarity in the BP reductions and in the responder rates but there was a consistent trend for superior values to be obtained with telmisartan (Table 4) . 8 Perhaps surprisingly, there is also evidence of a potential superiority of telmisartan over amlodipine which would be considered by many to be the reference long-acting antihypertensive agent. The preliminary results from this telmisartan-amlodipine comparison show that in both magnitude and duration telmisartan is at least as effective as amlodipine. 9 
Conclusions
In conclusion, the available information from clinical trials with angiotensin II antagonists is incomplete and there is a clear lack, not only of appropriately discriminatory studies, but also of detailed clinical pharmacological explorations into the duration and consistency of the anti-hypertensive effects, the doseresponse relationships, and the detailed pharmacokinetic-pharmacodynamic relationships. Overall, the available information is relatively consistent in sug- gesting that the magnitude of the anti-hypertensive effect with losartan generally tends to be less than that of comparator agents. In contrast, there is some evidence with the 'second generation' angiotensin II antagonists (such as candesartan and telmisartan) to suggest with greater confidence that the magnitude and duration of their anti-hypertensive effects are in accord with those of reference, once-daily agents. However, even with these newer agents there remain doubts about the pharmacokinetic-pharmacodynamic relationships and the clinically relevant doseresponse relationships. Clearly, further welldesigned, clinical studies are required to clarify whether these apparent differences in anti-hypertensive efficacy are genuine and, thereafter, to determine whether or not any such differences translate to clinically meaningful differences in outcome.
